JAUNDICE ASSOCIATED WITH NORETHANDROLONE (NILEVAR) THERAPY
Authors: R K SHAW, G L GOLD
Journal: Annals of Internal Medicine (1960)

Case Reports1 February 1960JAUNDICE ASSOCIATED WITH NORETHANDROLONE (NILEVAR) THERAPYRICHARD K. SHAW, M.D., G. LENNARD GOLD, M.D.RICHARD K. SHAW, M.D.Search for more papers by this author, G. LENNARD GOLD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-2-428 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptObstructive jaundice secondary to drug administration has become a more frequent occurrence in recent years. Many compounds of varied chemical structure have been incriminated in the past, including methyltestosterone,1, 2chlorpromazine,3arsphenamine,4para-aminosalicylic acid,5sulfadiazine,6thiouracil7and methimazole.8Of these drugs, chlorpromazine and methyltestosterone have received the greatest attention because of their frequent use. Norethandrolone, a potent anabolic testosterone derivative, has been mentioned as a cause of jaundice, but no case reports have been published to the authors' knowledge. It is the purpose of this paper to present the findings in a case of obstructive jaundice apparently due to norethandrolone....Bibliography1. WernerHangerKritzler LCFMR: Jaundice during methyltestosterone therapy, Am. J. Med. 8: 325, 1950. CrossrefMedlineGoogle Scholar2. BrickKyle IBLH: Jaundice of hepatic origin during the course of methyltestosterone therapy, New England J. Med. 246: 176, 1952. CrossrefMedlineGoogle Scholar3. Hollister LE: Allergy to chlorpromazine manifested by jaundice, Am. J. Med. 23: 870, 1957. CrossrefMedlineGoogle Scholar4. HangerGutman FMAB: Postarsphenamine jaundice apparently due to obstruction of the intrahepatic biliary tract, J. A. M. A. 115: 263, 1940. CrossrefGoogle Scholar5. LichtensteinCannemeyer MRW: Severe para-aminosalicylic acid hypersensitivity simulating mononucleosis or hepatitis, J. A. M. A. 152: 606, 1953. CrossrefMedlineGoogle Scholar6. Hoffman FG: Cholangiolitic hepatitis: case report and review, Gastroenterology 29: 247, 1955. CrossrefMedlineGoogle Scholar7. CargillLesses SLMF: Toxic reactions to thiouracil: report of cases with one fatality, J. A. M. A. 127: 890, 1945. CrossrefGoogle Scholar8. Shipp JC: Jaundice during methimazole (Tapazole) administration, Ann. Int. Med. 42: 701, 1955. LinkGoogle Scholar9. Koszalka MF: Medical obstructive jaundice: report of a death due to methyltestosterone, Journal Lancet 77: 51, 1957. Google Scholar10. HeaneyWhedon RPGD: Impairment of hepatic bromsulphalein clearance by two 17-substituted testosterones, J. Lab. and Clin. Med. 52: 169, 1958. MedlineGoogle Scholar11. KoryWatsonBradleyPeter RCRMMABJ: A six month evaluation of an anabolic drug, norethandrolone, in chronically underweight individuals, J. Clin. Investigation 36: 907, 1957. Google Scholar12. SpencerBergerCharlesGottesmanLaszlo HEMLED: Metabolic effects of 17-ethyl-19-nortestosterone in man, J. Clin. Endocrinol. and Metabolism 17: 975, 1957. CrossrefGoogle Scholar13. KowalewskiGouw KF: The effect of 17-ethyl-19-nortestosterone (Nilevar) on the uptake of radiosulfur in the fractured humerus in the rat, Surg., Gynec. and Obst. 105: 1, 1957. MedlineGoogle Scholar14. PodenMaxwellOhin JCMCA: Anabolic effect of a new synthetic steroid on nitrogen metabolism after operation, Arch. Surg. 75: 625, 1957. CrossrefGoogle Scholar15. Proceedings of a conference on the clinical use of anabolic agents, G. D. Searle and Co., p. 46, 1956. Google Scholar16. Popper H, mentioned in editorial by Gutman, A. B.: Drug reactions characterized by cholestasis associated with intrahepatic biliary tract obstruction, Am. J. Med. 23: 841, 1957. CrossrefMedlineGoogle Scholar17. Dunning MF: Jaundice associated with norethandrolone (Nilevar) administration, J. A. M. A. 167: 1242, 1958. CrossrefMedlineGoogle Scholar18. SchaffnerPopperChesrow FHE: Cholestasis produced by the administration of norethandrolone, Am. J. Med. 26: 249, 1959. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bethesda, Maryland*Received for publication September 26, 1958.From the General Medicine Branch, National Cancer Institute, National Institutes of Health, U. S. Department of Health, Education, and Welfare, Bethesda, Maryland.Requests for reprints should be addressed to Richard K. Shaw, M.D., University of Washington School of Medicine, Seattle, Washington. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAndrogen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996Wirkungen der Gestagene auf den StoffwechselEffects of various 17α-alkyl substitutions and structural modifications of steroids on sulfo broiophthalein (BSP) retention in rabbitsAnabolic SteroidsTransaminasen, Lactatdehydrogenase und Sorbitdehydrogenase im Serum bei myotonischer Dystrophie unter Methandrostenolon (17?-Methyl-17?-Hydroxy-androsta-1,4-dien-3-on)-BehandlungIntrahepatic Cholestasis vs. Posthepatic Jaundice: Methods of Diagnosis: With a Note on Hypercholesteremic Xanthomatosis in a Patient with Chlorpromazine CholestasisTHE HISTOPATHOLOGY OF DRUG-INDUCED LIVER DISEASEPHARMACOLOGY OF HEPATOTOXIC AGENTSJaundice Associated with Norethindrone Acetate TherapyAllergic Hepatitis Caused by Propionyl Erythromycin Ester of Lauryl SulfateDie Wirkung von Methandrostenolon auf die menschliche LeberTHE ACUTE CHOLESTATIC SYNDROME 1 February 1960Volume 52, Issue 2Page: 428-434KeywordsBileChlorpromazineCholesterolDrug administrationDrugsMultiple myelomaPhosphatasesSteroid therapyTestosterone ePublished: 1 December 2008 Issue Published: 1 February 1960 PDF downloadLoading ...